secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001104659-25-044838
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing
------------------------------------------------------------------------------

- Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.
- Net loss $5.3M for Q1 2025 vs $4.2M in Q1 2024; R&D expenses $3.7M, G&A $1.9M.
- NXP900 Phase 1a data at AACR showed robust pharmacodynamic response; Phase 1b enrollment in specific genetic alterations pending.
- NXP800 Phase 1b study in ARID1a-mutated ovarian cancer enrolling; update expected in two months.
- Completed $15.5M financing extending projected cash runway into Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925044838/0001104659-25-044838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925044838/tm2514104d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-044838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer